Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy

Drugs and Aging

Volumn 25, Issue 6, 2008, Pages 531-539

  Agostini, Marco ^a   Pasetto, Lara Maria ^b   Pucciarelli, Salvatore ^a   Terrazzino, Salvatore ^c,d   Ambrosi, Alessandro ^a,b   Bedin, Chiara ^a   Galdi, Francesca ^a   Friso, Maria Luisa ^b   Mescoli, Claudia ^b   Urso, Emanuele ^a   Leon, Alberta ^c   Lise, Mario ^a,e   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Research and Innovation   (Italy)

^d Studio Nutrizione and Benessere   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Capecitabine, therapeutic use; Elderly; Fluorouracil, therapeutic use; Genetic polymorphism; Oxaliplatin, therapeutic use

Indexed keywords

CAPECITABINE; CARBOPLATIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; ISOLEUCINE; OXALIPLATIN; THYMIDYLATE SYNTHASE; VALINE;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA POLYMORPHISM; ELDERLY CARE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECTUM CANCER; RESTRICTION MAPPING; SEX RATIO; SKIN TOXICITY; TANDEM REPEAT;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HEMATOLOGIC DISEASES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RESTRICTION MAPPING; SEX FACTORS; THYMIDYLATE SYNTHASE;

EID: 44949170619     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825060-00006     Document Type: Article

References (39)

1. EUCAN. Cancer incidence, mortality and prevalence in the European Union: 1998 estimates [online]. Available from URL: http://www-dep.iarc.fr/eucan/eucan. htm [Accessed 2008 Apr 1]
2. Grobovsky L, Kaplon M, Krozser-Hamati A, et al. Features of cancer in frail elderly patients (pts) (85 years of age) [abstract no. 2469]. Proc Am Soc Clin Oncol 2000; 19: 139
3. Pucciarelli S, Friso ML, Toppan P, et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol 2000; 7 (1): 38-44
4. The Advanced Colorectal Meta-Analysis Project. Modulation of fluorouracil with leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903
5. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New Engl J Med 1994; 331: 502-7
6. Sobrero A, Guglielmi A, Cirillo M, et al. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer 2001; 84 (8): 1023-8
7. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345 (15): 1091-7
8. The Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9
9. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8
10. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71
11. Hessman O, Bergkvist L, Strom S. Colorectal cancer in patients over 75 years of age: determinants of outcome. Eur J Surg Oncol 1997; 23 (1): 13-9
12. Koperna T, Kisser M, Schulz F. Hepatic resection in the elderly. World J Surg 1998; 22 (4): 406-12
13. Balducci L, Yates G. General guidelines for the management of older patients with cancer. Oncology 2000; 14: 221-7
14. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99-108
15. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912-20
16. Nagasubramanian R, Innocenti F, Ratain MJ, et al. Pharmacogenetics in cancer treatment. Ann Rev Med 2003; 54: 437-52
17. Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-9
18. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13 (12): 1915-8
19. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-42
20. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67 (4): 1163-71
21. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on RT. Int J Radiat Oncol Biol Phys 2000; 47: 13-47
22. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179-94
23. Agostini M, Pucciarelli S, Calandra P, et al. Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients. Int J Biol Markers 2004; 19 (4): 332-6
24. Terrazzino S, Agostini M, Pucciarelli S, et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006; 16 (11): 817-24
25. Harries LW, Stubbins MJ, Forman D, et al. Identification of genetic polymorphisms at the glutathione S-transferase P1 locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641-4
26. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5FU chemotherapy. Pharmacogenomics J 2001; 1 (1): 65-70
27. Cohen V, Panet-Raymond V, Sabbaghian N, et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-5
28. Mannervik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 1985; 82: 7202-6
29. Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422-8
30. Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione S-transferase (GST)-P1 antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996; 56: 3577-82
31. O'Brien M, Kruh GD, Tew KD. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 2000; 294: 480-7
32. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337-84
33. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-80
34. Srivastava SK, Singhal SS, Hu X, et al. Differential catalytic efficiency of allelic variants of human glutathione S-transferase P1 in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999; 366: 89-94
35. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000; 60: 5621-4
36. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 50 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63 (11): 2898-904
37. Dotor E, Cuatrecases M, Martinez-Iniesta M. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24 (10): 1603-11
38. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294-9
39. Pasetto LM, Friso ML, Pucciarelli S, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res 2006; 26: 3913-24